Dolat Capital: Godrej Consumer Q2 Review - Majority Portfolio Posted Double Digit Growth
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Godrej Consumer Products Ltd.’s net sales and Ebitda came in line while adjusted profit after tax was below our estimates.
The company has reported a 5% volume growth in the domestic market. 83% of the company’s portfolio, related to health, hygiene and value for money, delivered 17% sales growth during the quarter.
Household insecticides category posted a mere 4% growth, was a negative surprise, especially considering 22% growth reported by Jyothy Laboratories Ltd. in the same segment.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.